Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30531237 | 0.87 | KDM4E (0.69) | KDM4EALDH1A1GAAALOX15NPC1 | |
| SCHEMBL7598160 | 0.87 | KDM4E (0.69) | KDM4EALDH1A1GAAALOX15NPC1 | |
| SCHEMBL4737125 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1GAAALOX15HSD17B10 | |
| SCHEMBL2301745 | 0.83 | KDM4E (0.77) | KDM4EALDH1A1GAAALOX15POLB | |
| SCHEMBL2704348 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1GAAALOX15HSD17B10 | |
| SCHEMBL31184233 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1GAAALOX15HSD17B10 | |
| SCHEMBL31483916 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1GAAALOX15HSD17B10 | |
| SCHEMBL4878705 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1GAAALOX15POLB | |
| SCHEMBL9315414 | 0.79 | SMN1; SMN2 (0.56) | KDM4EALDH1A1GAAALOX15NPC1 | |
| SCHEMBL14459600 | 0.79 | KDM4E (0.71) | KDM4EALDH1A1GAAALOX15NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| CN-101263133-A | New pyridine analogues | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | KDM4E 1759/4885ALDH1A1 1274/4885GAA 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.